MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Exenatide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Exenatide is a GLP-1 receptor agonist and synthetic exendin-4, a 39-amino-acid peptide from the Gila monster that resists DPP-4 degradation. It was the first GLP-1 agonist approved (Byetta, 2005; Bydureon, 2012) and treats type 2 diabetes by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying and reducing appetite. The immediate-release form is dosed 5 mcg twice daily before meals, raised to 10 mcg twice daily after a month; the extended-release microsphere form is a flat 2 mg once weekly. Immediate-release exenatide has a ~2.4-hour half-life and is renally cleared, while the weekly depot releases peptide over about 10 weeks. In DURATION-1, once-weekly exenatide cut HbA1c by ~1.9% (PMID 18782641), and in EXSCEL of 14,752 patients it showed cardiovascular safety with a nominal mortality reduction (PMID 28910237). It is FDA- and EMA-approved; research vials are for laboratory use only.
Reconstitute: Add 2 mL bacteriostatic water → 0.5 mg/mL concentration.
Typical dose: 5→10 mcg SC twice daily (immediate-release); 2 mg SC once weekly (extended-release)
Easy measuring: At 0.5 mg/mL, 1 unit = 0.01 mL = 0.0050 mg (5 mcg) on a U-100 insulin syringe.
Storage: Lyophilized research vial: refrigerate 2–8°C, protect from light. Reconstituted solution: store at 2–8°C and use within ~28 days. Commercial Byetta pen: refrigerate 2–8°C before first use, then store ≤25°C and use within 30 days; do not freeze. Bydureon BCise: refrigerate 2–8°C, may be kept at room temperature (≤30°C) for up to 4 weeks before use.
Half-life: Immediate-release ~2.4 h (Tmax 2.1 h, renal clearance); extended-release microspheres release over ~10 weeks (steady state ~6–7 weeks)
Route: Subcutaneous — immediate-release twice daily before meals; extended-release 2 mg once weekly (abdomen, thigh, or upper arm)
Status: FDA/EMA-approved — Byetta (2005), Bydureon (2012), Bydureon BCise (2017); research-grade vials are lab-use only
About Exenatide
Exenatide is a synthetic version of exendin-4, a 39-amino-acid GLP-1 receptor agonist originally identified in the saliva of the Gila monster (Heloderma suspectum). Unlike many compounds catalogued on this site, exenatide's real-world clinical route genuinely is subcutaneous injection, so the reconstitution figures below map directly onto how the drug is actually administered [1][3]. Commercially it ships as a prefilled pen — Byetta at 250 mcg/mL for twice-daily use, and Bydureon / Bydureon BCise as an extended-release microsphere suspension for once-weekly use — while the vial-and-bacteriostatic-water protocol shown here is an educational reconstitution reference for research-grade lyophilized powder.\n\nThe standard immediate-release Exenatide dosage starts low to limit nausea: 5 mcg injected subcutaneously twice daily within the 60 minutes before the morning and evening meals, then increased to 10 mcg twice daily after about one month if tolerated [1]. The extended-release formulation is dosed at a flat 2 mg once every 7 days, at any time of day with or without food [2]. Immediate-release exenatide has a short ~2.4-hour half-life, which is why it is given before meals twice a day, whereas the microsphere depot of the weekly product releases peptide gradually over roughly ten weeks [4].\n\nReconstituting a 1 mg vial with 2 mL of bacteriostatic water yields a 0.5 mg/mL solution, so 5 mcg measures 1 unit and 10 mcg measures 2 units on a U-100 insulin syringe — both titration steps land on clean, readable marks.\n\nFrequency: Inject twice daily subcutaneously, within 60 minutes before the morning and evening meals (doses at least ~6 hours apart); never inject after a meal [1].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe (this yields a 0.5 mg/mL solution from a 1 mg vial).
Inject the water slowly down the inner wall of the vial; do not spray directly onto the powder and avoid foaming.
Gently swirl or roll the vial until the powder is fully dissolved and the solution is clear — never shake, as agitation can denature the peptide.
Load a U-100 insulin syringe to the units for your titration step (5 mcg = 1 unit / 0.01 mL; 10 mcg = 2 units / 0.02 mL).
Swab the site (abdomen, thigh, or upper arm), inject subcutaneously within 60 minutes before a meal, rotate sites with each dose, and return the vial to the refrigerator.
Interactive Exenatide Syringe Calculator
Currently visualizing the 1 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 1mg dry powder in 2mL water yields 0.50 mg/mL. To evaluate a 250mcg dose, pull to 50.0 units (50 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Immediate-release initiation — weeks 1–4 (5 mcg twice daily, within 60 min before morning and evening meals) | 5 mcg | 1 units (0.01 mL) |
| Immediate-release maintenance — week 5 onward (increase to 10 mcg twice daily if tolerated) | 10 mcg | 2 units (0.02 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 1 mg vial.
Peptide Vials (Exenatide, 1 mg each):
- checkTotal drug used is tiny (micrograms per dose), so mass is never the limit — vials are replaced for sterility/potency, not because they run empty.
- check8 weeks (twice-daily IR protocol): ~2 vials (replace the reconstituted vial about every 4 weeks)
- check12 weeks: ~3 vials
- check16 weeks: ~4 vials
Insulin Syringes (U-100):
- check8 weeks: 112 syringes (2 per day, twice-daily dosing)
- check12 weeks: 168 syringes
- check16 weeks: 224 syringes
Bacteriostatic Water (10 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks (2 vials): ~4 mL → 1 × 10 mL bottle
- check12 weeks (3 vials): ~6 mL → 1 × 10 mL bottle
- check16 weeks (4 vials): ~8 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper plus one for the injection site at each of the two daily injections.
- checkPer day: ~4 swabs (vial stopper + site, twice daily)
- check8 weeks: ~224 swabs → 3 × 100-count boxes
- check12 weeks: ~336 swabs → 4 × 100-count boxes
- check16 weeks: ~448 swabs → 5 × 100-count boxes
Mechanism of Action (MOA)
Exenatide is a 39-amino-acid synthetic exendin-4, a peptide found in the venom/saliva of the Gila monster that shares roughly 50% sequence homology with native human GLP-1 (7-36) [3]. Its critical engineering advantage is a glycine at position 2 that blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades native GLP-1 within about 1–2 minutes. This resistance lets exenatide act as a stable, long-lived GLP-1 receptor agonist [3][4].\n\nBinding to the GLP-1 receptor — a class B G-protein-coupled receptor — on pancreatic beta cells raises intracellular cyclic AMP and activates protein kinase A, amplifying glucose-dependent insulin secretion. Because this potentiation only occurs when blood glucose is elevated, the intrinsic risk of hypoglycemia is low [3]. Exenatide simultaneously suppresses inappropriate glucagon release from alpha cells, slows gastric emptying to blunt post-prandial glucose excursions, and acts on hypothalamic and brainstem appetite centers to reduce food intake — the combination that drives both glycemic improvement and modest weight loss [1][3].\n\nPharmacokinetically the two formulations behave very differently. Immediate-release exenatide (Byetta) reaches peak plasma concentration (Tmax) about 2.1 hours after a subcutaneous dose and has an elimination half-life of approximately 2.4 hours, so it is dosed twice daily before meals [1][4]. It is cleared predominantly by glomerular filtration with subsequent proteolytic degradation in the renal tubules; mean apparent clearance is about 9.1 L/h, and because elimination is renal it is not recommended when creatinine clearance falls below 30 mL/min [1][4]. The extended-release product (Bydureon / Bydureon BCise) encapsulates the same peptide in biodegradable poly-(D,L-lactide-co-glycolide) microspheres that release exenatide in three overlapping phases — an initial surface release, diffusion-controlled release, and final polymer erosion — sustaining therapeutic plasma levels for roughly 10 weeks and allowing flat 2 mg once-weekly dosing without titration [2][4]. Steady-state concentrations with the weekly product are reached after about 6–7 weeks of continuous dosing.\n\nDownstream, sustained GLP-1 receptor agonism produces HbA1c reductions of roughly 1.0–1.9% depending on formulation and baseline, modest weight loss of about 2–4 kg, and small reductions in systolic blood pressure [5][6][7]. The deliberate 5 mcg → 10 mcg immediate-release titration exists because gastrointestinal tolerance improves with gradual receptor adaptation, markedly reducing nausea versus starting at the full dose [1]. Unlike basal insulin, exenatide does not replace endogenous insulin; it augments the body's own glucose-dependent secretory response, which is why glycemic benefit attenuates as glucose normalizes and why it is positioned as an adjunct rather than a first-line monotherapy [3].
Clinical Trial Efficacy Highlights
- starEXSCEL (Holman et al., NEJM 2017) randomized 14,752 patients with type 2 diabetes, with and without prior cardiovascular disease, to once-weekly exenatide 2 mg or placebo. The primary major adverse cardiovascular event composite occurred in 11.4% on exenatide versus 12.2% on placebo (HR 0.91, 95% CI 0.83–1.00); the result met non-inferiority for safety but did not reach superiority, while all-cause mortality was nominally lower (6.9% vs 7.9%, HR 0.86) [8].
- starDURATION-1 (Drucker et al., Lancet 2008) compared once-weekly exenatide 2 mg with twice-daily exenatide 10 mcg over 30 weeks in 295 patients. HbA1c fell by −1.9% with the weekly formulation versus −1.5% with twice-daily dosing (p=0.0023), and 77% versus 61% of patients reached an HbA1c of 7.0% or less; both groups lost roughly 3.6–3.7 kg [5].
- starThe DURATION-1 52-week extension (Buse et al., Diabetes Care 2010) showed that patients continuing once-weekly exenatide maintained an HbA1c reduction of about −2.0% from baseline and progressive weight loss of roughly −4.1 kg, demonstrating durability of glycemic control over a full year [6].
- starDURATION-6 (Buse et al., Lancet 2013) directly compared once-weekly exenatide 2 mg with once-daily liraglutide 1.8 mg over 26 weeks in 911 patients. Liraglutide produced a slightly greater HbA1c reduction (−1.48% vs −1.28%; difference 0.21% favoring liraglutide) and more weight loss, but exenatide caused less nausea, vomiting and diarrhea — establishing both as effective with differing tolerability profiles [7].
- starAcross the immediate-release program, twice-daily exenatide titrated from 5 to 10 mcg lowered HbA1c by roughly 0.8–1.0% from baseline as add-on therapy to metformin and/or a sulfonylurea, with consistent modest weight reduction rather than the weight gain seen with insulin or sulfonylureas [1][3].
- starPharmacokinetic characterization confirms the mechanistic basis for the two dosing schedules: immediate-release exenatide has a Tmax near 2.1 hours and a ~2.4-hour half-life cleared renally, whereas the extended-release microsphere depot sustains plasma exposure over about 10 weeks, supporting flat 2 mg weekly dosing without titration [1][2][4].
- starBecause insulin potentiation is glucose-dependent, exenatide monotherapy carries a low hypoglycemia rate; in controlled trials clinically significant hypoglycemia rose mainly when exenatide was combined with a sulfonylurea, which frequently required a sulfonylurea dose reduction [1][3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects are the most common adverse events: nausea is dose-dependent and frequent (often 40–50% of immediate-release users early on), with vomiting, diarrhea, constipation and decreased appetite also reported. Symptoms are usually mild-to-moderate, peak during initiation, and are reduced by the 5 mcg → 10 mcg titration [1][3].
- warningThe extended-release (Bydureon / Bydureon BCise) formulation commonly causes injection-site reactions, including small subcutaneous nodules at the depot site that can persist for weeks; rotating injection sites reduces but does not eliminate them [2].
- warningAcute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been reported with exenatide and the GLP-1 class. Patients with persistent severe abdominal pain should stop the drug and be evaluated; it should not be restarted if pancreatitis is confirmed [1][2].
- warningExtended-release exenatide carries an FDA boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2); human relevance has not been established [2].
- warningBecause exenatide is cleared renally, it is not recommended when creatinine clearance is below 30 mL/min or in end-stage renal disease; post-marketing reports include acute kidney injury and worsening chronic renal failure, sometimes linked to dehydration from severe gastrointestinal losses [1][4].
- warningHypoglycemia is uncommon with monotherapy because insulin release is glucose-dependent, but risk rises substantially when exenatide is combined with a sulfonylurea or insulin, which often require dose reduction [1][3].
- warningOther reported effects include headache, dizziness, jittery feeling, antibody formation against exenatide (which can attenuate response in a minority of patients), gallbladder disease, and rare serious hypersensitivity reactions including anaphylaxis and angioedema [1][2][3].
- warningRegulatory status: exenatide is an FDA- and EMA-approved prescription medicine (Byetta, Bydureon, Bydureon BCise). Research-grade lyophilized vials are sold strictly for laboratory use and are not a substitute for a prescribed, pharmaceutical-quality product; the reconstitution protocol here is educational and is not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Exenatide dosage?expand_more
For the immediate-release product (Byetta) the typical Exenatide dosage is 5 mcg injected subcutaneously twice daily, within 60 minutes before the morning and evening meals, for about one month; if tolerated it is then increased to 10 mcg twice daily. For the extended-release product (Bydureon / Bydureon BCise) the dose is a flat 2 mg once every 7 days, at any time of day with or without food and without titration. The slow 5→10 mcg step on the immediate-release form exists to reduce nausea during the first month.
Is Exenatide FDA approved?expand_more
Yes. Exenatide was the first GLP-1 receptor agonist approved by the FDA — Byetta (immediate-release, twice daily) in April 2005, followed by the extended-release Bydureon in 2012 and Bydureon BCise in 2017 (with a pediatric indication for ages 10 and older added in 2021). It is also approved by the EMA. Note that research-grade lyophilized exenatide vials are sold for laboratory use only and are not FDA-approved pharmaceutical products.
What is the half-life of Exenatide?expand_more
Immediate-release exenatide has a short elimination half-life of approximately 2.4 hours, with peak plasma concentration around 2.1 hours after a subcutaneous dose — which is why it is dosed twice daily before meals. The extended-release formulation is different: the peptide is encapsulated in biodegradable microspheres that release it gradually over roughly 10 weeks, so plasma levels are sustained for once-weekly dosing and steady state is reached after about 6–7 weeks. Exenatide is cleared mainly by the kidneys via glomerular filtration.
How do you reconstitute Exenatide from a research vial?expand_more
Draw 2 mL of bacteriostatic water and inject it slowly down the inner wall of a 1 mg vial to make a 0.5 mg/mL solution. Swirl gently until the solution is clear — never shake. On a U-100 insulin syringe, 5 mcg measures 1 unit (0.01 mL) and 10 mcg measures 2 units (0.02 mL). Store the reconstituted solution at 2–8°C and use it within about 28 days. Commercially, immediate-release exenatide instead comes as a ready-to-use 250 mcg/mL pen, and the extended-release form ships as a microsphere suspension.
Can Exenatide be stacked with other GLP-1 drugs like semaglutide or liraglutide?expand_more
No. Exenatide should not be combined with semaglutide, liraglutide, tirzepatide or any other GLP-1/incretin agent — they act on overlapping receptors, so stacking sharply increases gastrointestinal toxicity, hypoglycemia risk (especially with sulfonylureas or insulin) and pancreatitis risk without proven added benefit. The two exenatide formulations themselves are also never used together. Clinicians transition between agents rather than overlapping them, and any change should be supervised by a prescriber.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Exenatide, plus the universal dosing calculator.
Academic References & Study Citations
FDA Prescribing Information — BYETTA (exenatide) injection, AstraZeneca. DailyMed label: immediate-release dosing (5→10 mcg twice daily before meals), how supplied (250 mcg/mL pens), renal limits (CrCl <30 mL/min), pharmacokinetics (t½ ~2.4 h, Tmax 2.1 h, renal elimination), and warnings. View Scientific Paper →
FDA Prescribing Information — BYDUREON BCISE (exenatide extended-release) injectable suspension, AstraZeneca. DailyMed label: 2 mg subcutaneously once every 7 days, boxed warning for thyroid C-cell tumors, and contraindications (MTC/MEN 2). View Scientific Paper →
Exenatide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; NCBI Bookshelf. Mechanism, indications, immediate- versus extended-release dosing, adverse effects and monitoring of exenatide. View Scientific Paper →
A Comprehensive Review on the Pharmacokinetics and Drug–Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Des Devel Ther (2025), PMC. Exenatide IR half-life ~2.4 h, renal glomerular clearance, and PLGA microsphere extended-release mechanism (~10-week release). View Scientific Paper →
Drucker DJ, Buse JB, Taylor K, et al. (2008) Lancet 372(9645):1240-1250. 'Exenatide once weekly versus twice daily for the treatment of type 2 diabetes' (DURATION-1). HbA1c −1.9% weekly vs −1.5% twice daily. View Scientific Paper →
Buse JB, Drucker DJ, Taylor KL, et al. (2010) Diabetes Care 33(6):1255-1261. 'DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks'. View Scientific Paper →
Buse JB, Nauck M, Forst T, et al. (2013) Lancet 381(9861):117-124. 'Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study'. View Scientific Paper →
Holman RR, Bethel MA, Mentz RJ, et al. (2017) N Engl J Med 377(13):1228-1239. 'Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes' (EXSCEL). 14,752 patients; MACE HR 0.91. View Scientific Paper →